

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5975920

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CONFIRMATION OF OWNERSHIP (AS FILING RELATES TO COMPOUNDS THAT ARE "DERIVATIVES")
CONVEYING PARTY DATA	
Name	Execution Date
UNIVERSITY OF HEIDELBERG	07/23/2012
RECEIVING PARTY DATA	
Name:	MOLECULAR INSIGHT PHARMACEUTICAL, INC.
Street Address:	160 SECOND STREET
City:	CAMBRIDGE
State/Country:	MASSACHUSETTS
Postal Code:	02142
PROPERTY NUMBERS Total: 2	
Property Type	Number
Application Number:	16551198
Application Number:	16510495
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6172485000
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE HALL & STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2010358-0000
NAME OF SUBMITTER:	BRENDA HERSCHBACH JARRELL, PHD, JD
SIGNATURE:	/Brenda Herschbach Jarrell/
DATE SIGNED:	02/21/2020
Total Attachments: 3	
source=2010358-0000 Material Transfer Agreement#page1.tif	
source=2010358-0000 Material Transfer Agreement#page2.tif	
source=2010358-0000 Material Transfer Agreement#page3.tif	

Material Transfer Agreement

This Agreement is entered into as of [REDACTED] 2012 by and between the University of Heidelberg having an address at Neuenheimer Feld 672, 69120 Heidelberg USA ("INSTITUTION"), and Molecular Insight Pharmaceutical, Inc., having an office at 160 Second Street, Cambridge, Massachusetts 02142 USA ("MIP").

WHEREAS, MIP is the owner of the compounds more fully described in Appendix A attached hereto, and any progeny and derivatives thereof (the "Materials") with all rights, title and interest vested therein.

WHEREAS, INSTITUTION desires to receive samples of the Materials for the purposes described herein.

NOW, THEREFORE, the parties hereto agree to the terms and conditions contained herein.

1. Transfer of Materials. MIP shall transfer to INSTITUTION such amount of the Materials as mutually agreed upon by MIP and INSTITUTION. Acceptance of the Materials by INSTITUTION shall be for the purpose stated in Section 2 herein only and shall not be deemed to be a grant by MIP to INSTITUTION of any rights in the Materials or any progeny or derivative works from the Materials.
2. Use of Materials. The Material, and any derivative works or progeny thereof, is and shall remain the property of MIP. INSTITUTION acknowledges that it shall not obtain any rights of any sort, including commercialization, in or to the Materials as a result of the transfer of the Materials by MIP and that all such rights it may wish to obtain shall be the subject of a separate and future agreement(s). [REDACTED]

[REDACTED]

3. [REDACTED]

4. [REDACTED]

[REDACTED]

5.

[REDACTED]

6.

[REDACTED]

7.

[REDACTED]

[REDACTED]

8.

[REDACTED]

[REDACTED]

[REDACTED]

[REDACTED]

8.

[Redacted]

9.

[Redacted]

10.

[Redacted]

11.

[Redacted]

IN WITNESS WHEREOF, the parties have caused this instrument to be executed by their duly authorized representatives.

UNIVERSITY OF HEIDELBERG

i. A. Tilly

Signature

Erntraut Türken
ACBumännliche Direktorin

Universitätsklinikum Heidelberg
im Neuenheimer Feld 672 · 69120 Heidelberg

Title

23.07.2012

Date

MIP

Johanna Babida

Signature

Johanna Babida

Name

CSO & President

Title

July 23, 2012

Date

Prof. Dr. Uwe Haberkorn
Radiologische Universitätsklinik
Abteilung Nuklearmedizin
im Neuenheimer Feld 400
69120 Heidelberg
Tel. 0 62 21 / 56 77 31